Survival outcomes in node-positive non-metastatic bladder cancer: An analysis of the national cancer database.

IF 1.3 Q3 UROLOGY & NEPHROLOGY
Arab Journal of Urology Pub Date : 2022-05-20 eCollection Date: 2022-01-01 DOI:10.1080/2090598X.2022.2077001
Amr A Elbakry, Tyler Trump, Christopher Ferari, Malcom D Mattes, Adam Luchey
{"title":"Survival outcomes in node-positive non-metastatic bladder cancer: An analysis of the national cancer database.","authors":"Amr A Elbakry,&nbsp;Tyler Trump,&nbsp;Christopher Ferari,&nbsp;Malcom D Mattes,&nbsp;Adam Luchey","doi":"10.1080/2090598X.2022.2077001","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Clinically node-positive non-metastatic bladder cancer (cN+) has been the target of several studies aiming to establish a standard of care for this population. Limited studies have shown a survival benefit for various multimodal therapy approaches. The role of radiation therapy has not been well established. Our study aims to study the trends of the reported treatment options offered to patients with cN+ bladder cancer in a national database and to evaluate the effect of various treatments, including radiation, on survival.</p><p><strong>Methods: </strong>The National Cancer Database (NCDB) was used to identify cN+ bladder cancer patients who received chemotherapy alone or in combination with radical cystectomy (RC) or radiotherapy. 3,481 patients were included and divided into 4 groups: chemotherapy only, chemotherapy and RC, chemotherapy and radiation therapy, and chemotherapy, RC, and radiation therapy. Demographic data was compared using ANOVA for continuous variables, and Chi-square for categorical variables. Multivariable analysis was done to compare groups using a multinomial logistic regression model. Kaplan-Meier test was used for survival analysis and Cox-Regression was used for multivariable survival analysis.</p><p><strong>Results: </strong>Patients undergoing RC were significantly younger (<i>P</i> <0.001). There was a significant difference between the groups regarding racial distribution, facility-type and insurance status. There was no difference in gender, Charlson\\Deyo score, financial or educational status. Patients who underwent combination therapy with chemotherapy and RC were found to have the longest median survival time at 27 months. Multivariable analysis showed that final treatment, age, sex, Charlson\\Deyo comorbidity score, TNM edition and facility-type were significant survival predictors. Race, insurance and financial status failed to maintain significance. There was no survival difference between the chemotherapy group and chemo-radiotherapy group.</p><p><strong>Conclusions: </strong>The combination of surgery and chemotherapy achieves statistically significant superior survival in cN+ bladder cancer. Adding radiotherapy to chemotherapy did not improve survival in this group of patients.</p><p><strong>Abbreviations: </strong>(cN+): Clinically node-positive non-metastatic, (MIBC): Muscle invasive bladder cancer, (NCDB): National Cancer Database, (NAC): Neoadjuvant chemotherapy, (RC): Radical Cystectomy.</p>","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639493/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arab Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/2090598X.2022.2077001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: Clinically node-positive non-metastatic bladder cancer (cN+) has been the target of several studies aiming to establish a standard of care for this population. Limited studies have shown a survival benefit for various multimodal therapy approaches. The role of radiation therapy has not been well established. Our study aims to study the trends of the reported treatment options offered to patients with cN+ bladder cancer in a national database and to evaluate the effect of various treatments, including radiation, on survival.

Methods: The National Cancer Database (NCDB) was used to identify cN+ bladder cancer patients who received chemotherapy alone or in combination with radical cystectomy (RC) or radiotherapy. 3,481 patients were included and divided into 4 groups: chemotherapy only, chemotherapy and RC, chemotherapy and radiation therapy, and chemotherapy, RC, and radiation therapy. Demographic data was compared using ANOVA for continuous variables, and Chi-square for categorical variables. Multivariable analysis was done to compare groups using a multinomial logistic regression model. Kaplan-Meier test was used for survival analysis and Cox-Regression was used for multivariable survival analysis.

Results: Patients undergoing RC were significantly younger (P <0.001). There was a significant difference between the groups regarding racial distribution, facility-type and insurance status. There was no difference in gender, Charlson\Deyo score, financial or educational status. Patients who underwent combination therapy with chemotherapy and RC were found to have the longest median survival time at 27 months. Multivariable analysis showed that final treatment, age, sex, Charlson\Deyo comorbidity score, TNM edition and facility-type were significant survival predictors. Race, insurance and financial status failed to maintain significance. There was no survival difference between the chemotherapy group and chemo-radiotherapy group.

Conclusions: The combination of surgery and chemotherapy achieves statistically significant superior survival in cN+ bladder cancer. Adding radiotherapy to chemotherapy did not improve survival in this group of patients.

Abbreviations: (cN+): Clinically node-positive non-metastatic, (MIBC): Muscle invasive bladder cancer, (NCDB): National Cancer Database, (NAC): Neoadjuvant chemotherapy, (RC): Radical Cystectomy.

Abstract Image

Abstract Image

Abstract Image

淋巴结阳性非转移性膀胱癌的生存结局:国家癌症数据库的分析。
临床淋巴结阳性的非转移性膀胱癌(cN+)已经成为几项研究的目标,旨在为这一人群建立一个标准的护理。有限的研究表明,各种多模式治疗方法对生存有好处。放射治疗的作用尚未得到很好的确定。我们的研究旨在研究国家数据库中cN+膀胱癌患者的治疗方案的趋势,并评估各种治疗方法(包括放疗)对生存的影响。方法:使用国家癌症数据库(NCDB)对单独化疗或联合根治性膀胱切除术(RC)或放疗的cN+膀胱癌患者进行鉴定。纳入3481例患者,分为单纯化疗组、化疗+ RC组、化疗+放疗组、化疗+ RC +放疗组。人口统计数据对连续变量采用方差分析,对分类变量采用卡方分析。采用多项逻辑回归模型进行多变量分析。生存分析采用Kaplan-Meier检验,多变量生存分析采用Cox-Regression。结论:cN+膀胱癌手术加化疗的生存率有统计学意义。在化疗的基础上加放疗并没有提高该组患者的生存率。缩写:(cN+):临床淋巴结阳性非转移性,(MIBC):肌肉浸润性膀胱癌,(NCDB):国家癌症数据库,(NAC):新辅助化疗,(RC):根治性膀胱切除术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Arab Journal of Urology
Arab Journal of Urology UROLOGY & NEPHROLOGY-
CiteScore
2.80
自引率
0.00%
发文量
40
期刊介绍: The Arab Journal of Urology is a peer-reviewed journal that strives to provide a high standard of research and clinical material to the widest possible urological community worldwide. The journal encompasses all aspects of urology including: urological oncology, urological reconstructive surgery, urodynamics, female urology, pediatric urology, endourology, transplantation, erectile dysfunction, and urinary infections and inflammations. The journal provides reviews, original articles, editorials, surgical techniques, cases reports and correspondence. Urologists, oncologists, pathologists, radiologists and scientists are invited to submit their contributions to make the Arab Journal of Urology a viable international forum for the practical, timely and state-of-the-art clinical urology and basic urological research.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信